Baidu
map

Nat Med:阿尔茨海默氏患者是如何失去记忆的?

2014-07-14 佚名 生物谷

韩国研究人员发现,反应性星形胶质细胞(reactive astrocytes)在阿尔茨海默氏症患者被普遍观察到,结果是异常和大量生成抑制性神经递质γ-氨基丁酸,并通过Bestrophin-1通道将其释放。被释放的GABA强烈抑制邻近的神经元,引起突触传递、可塑性和记忆损害。这一发现将有助开发新的药物用于治疗这类疾病。 阿尔茨海默氏症,是老年痴呆最常见的原因,是致命的,目前还没有治愈方法。在阿

韩国研究人员发现,反应性星形胶质细胞(reactive astrocytes)在阿尔茨海默氏症患者被普遍观察到,结果是异常和大量生成抑制性神经递质γ-氨基丁酸,并通过Bestrophin-1通道将其释放。被释放的GABA强烈抑制邻近的神经元,引起突触传递、可塑性和记忆损害。这一发现将有助开发新的药物用于治疗这类疾病。

阿尔茨海默氏症,是老年痴呆最常见的原因,是致命的,目前还没有治愈方法。在阿尔茨海默氏病中,脑细胞受损和破坏,从而导致破坏性的记忆丧失。然而,迄今为止,阿尔茨海默氏症相关痴呆症的机制没有得到清晰的认识。

韩国研究小组发现,在阿尔茨海默氏病模型小鼠的反应性星形胶质细胞(reactive astrocytes)通过单胺氧化酶B(MAO-B)生成抑制性递质γ-氨基丁酸,并通过Bestrophin-1通道释放GABA,在突触传递期间抑制正常的信息流。

根据这一发现,研究人员能够通过抑制MAO-B或Bestrophin-1,减少GABA生成和释放,并成功改善阿尔茨海默氏病模型小鼠受损的神经元放电,突触传递和记忆。

在行为测试研究中,老鼠往往喜欢黑暗的地方。如果老鼠在黑暗的地方遇到触电,它会记住这个事件,避免黑暗的地方。然而,阿尔茨海默氏症鼠不记得这种触电冲击是否关系到黑暗地方,并仍会去黑暗的地方。

研究表明这些小鼠用MAO-B抑制剂治疗完全恢复了小鼠的记忆。目前,司来吉兰(Selegiline)是帕金森氏病的一种辅助治疗药物,被评定为最有前途的MAO-B抑制剂药物。但它先前已经证明对阿尔茨海默氏病不那么有效。

新研究证实司来吉兰在短时间内是有效的,但是,当它被长期使用,它在阿尔茨海默病模型小鼠中就失去其效力。当给予1周,司来吉兰将神经元放电活动恢复到正常水平。但是,当小鼠被治疗2和4周时,神经元的放电活动回来未处理小鼠水平。

主要研究人员C. Justin Lee C博士说:从这个研究,我们揭示了阿尔茨海默氏症患者如何失去记忆的新机制。我们也提出治疗老年痴呆症的新治疗靶点,其中包括GABA的生成和释放。

原始出处:

Jo S1, Yarishkin O2, Hwang YJ3, Chun YE4, Park M5, Woo DH6, Bae JY7, Kim T6, Lee J6, Chun H6, Park HJ8, Lee DY6, Hong J6, Kim HY3, Oh SJ9, Park SJ6, Lee H6, Yoon BE6, Kim Y3, Jeong Y10, Shim I8, Bae YC7, Cho J5, Kowall NW11, Ryu H12, Hwang E6, Kim D13, Lee CJ14.GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease.Nat Med. 2014 Jun 29. doi: 10.1038/nm.3639. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1817645, encodeId=e6cf181e64540, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Mar 13 12:11:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816622, encodeId=44d31816622d0, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Oct 01 23:11:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880174, encodeId=da4718801e47a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Apr 04 01:11:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990370, encodeId=781919903e0ea, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Tue Dec 09 15:11:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469999, encodeId=43b6146999929, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Jul 16 00:11:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606239, encodeId=665c16062395b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jul 16 00:11:00 CST 2014, time=2014-07-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1817645, encodeId=e6cf181e64540, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Mar 13 12:11:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816622, encodeId=44d31816622d0, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Oct 01 23:11:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880174, encodeId=da4718801e47a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Apr 04 01:11:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990370, encodeId=781919903e0ea, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Tue Dec 09 15:11:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469999, encodeId=43b6146999929, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Jul 16 00:11:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606239, encodeId=665c16062395b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jul 16 00:11:00 CST 2014, time=2014-07-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1817645, encodeId=e6cf181e64540, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Mar 13 12:11:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816622, encodeId=44d31816622d0, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Oct 01 23:11:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880174, encodeId=da4718801e47a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Apr 04 01:11:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990370, encodeId=781919903e0ea, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Tue Dec 09 15:11:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469999, encodeId=43b6146999929, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Jul 16 00:11:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606239, encodeId=665c16062395b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jul 16 00:11:00 CST 2014, time=2014-07-16, status=1, ipAttribution=)]
    2015-04-04 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1817645, encodeId=e6cf181e64540, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Mar 13 12:11:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816622, encodeId=44d31816622d0, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Oct 01 23:11:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880174, encodeId=da4718801e47a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Apr 04 01:11:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990370, encodeId=781919903e0ea, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Tue Dec 09 15:11:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469999, encodeId=43b6146999929, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Jul 16 00:11:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606239, encodeId=665c16062395b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jul 16 00:11:00 CST 2014, time=2014-07-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1817645, encodeId=e6cf181e64540, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Mar 13 12:11:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816622, encodeId=44d31816622d0, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Oct 01 23:11:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880174, encodeId=da4718801e47a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Apr 04 01:11:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990370, encodeId=781919903e0ea, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Tue Dec 09 15:11:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469999, encodeId=43b6146999929, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Jul 16 00:11:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606239, encodeId=665c16062395b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jul 16 00:11:00 CST 2014, time=2014-07-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1817645, encodeId=e6cf181e64540, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Mar 13 12:11:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816622, encodeId=44d31816622d0, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Oct 01 23:11:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880174, encodeId=da4718801e47a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Apr 04 01:11:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990370, encodeId=781919903e0ea, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Tue Dec 09 15:11:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469999, encodeId=43b6146999929, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Jul 16 00:11:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606239, encodeId=665c16062395b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jul 16 00:11:00 CST 2014, time=2014-07-16, status=1, ipAttribution=)]

相关资讯

基因疗法有望攻克地中海贫血症

两名地中海贫血症患者参加了蓝鸟生物公司(Bluebird Bio)针对该罕见血液病的基因治疗实验,在接受治疗的12天之内,他们能够停止输血治疗。 2010年,该疗法一个更早的版本就刊登在了《自然》(Nature)杂志上,当时这一疗法使一名地中海贫血患者有长达六年的时间不用接受输血治疗。但在接受完该疗法不能马上停止输血,而是要等到12个月之后。新的数据给人的希望是,蓝鸟公司的升级版疗法比之前

Dimension与拜耳签订2亿5千万美元合作协议

在过去7个月中,Dimension Therapeutics公司作出一系列举措不断推进基因治疗疗法。上周五Dimension公司又有新动作,公司与拜耳公司签订了一项总价值约2亿5千万美元的协议。根据这一协议,拜耳公司将资助Dimension公司开发的治疗A型血友病的所有临床前研究以及随后的前期临床研究。一旦获得成功,拜耳公司将负责最后的临床上三期研究,一旦成功,拜耳公司将获得这种疗法的全球商业权

医疗器械行业火热 药企转战分子诊断市场

改革开放以来,我国的医疗器械业取得了良好的发展,在当今这个经济全球化的形势下,国内国外的医疗器械行业纷纷致力于开发新兴市场,尤其是中国市场,进军分子诊断领域。 据悉,中国医疗器械设备市场经过近10年的发展已经发生巨大变化,产品从引进之初由进口品牌垄断市场的局面逐步发展到当前国内外品牌激烈竞争的市场格局。 在扩大产品线、产地本土化、降低成本等各方面同时努力,以提高品牌竞争力;国内医疗器械设备的生

JBC:病毒利用“假冒”蛋白在机体细胞中隐藏的分子机制

有些病毒可以在机体中隐藏很多年,其往往可以产生一些假冒的机体蛋白质来骗过机体免疫系统的审查;近日,来自墨尔本大学等处的研究人员通过就揭示了病毒假冒蛋白的基本结构,相关研究成果刊登于国际杂志Journal of Biological Chemistry上。 利用同步辐射光来对机体中的常见无害病毒进行追踪研究,研究者揭示了这种病毒“假冒”蛋白质的结构,这对于后期开发新型疫苗及抗病毒药物提供了一定

Nat Commun:lncRNA调控免疫反应

近日,Mark Lindsay教授领导的一个研究小组在确定调节免疫反应的基因中取得了突破性进展。 免疫反应辨识和捍卫机体免受危险微生物的侵害。在正常情况下,一旦威胁已经过去了,免疫反应会关闭。然而,这种情况并不总是发生,结果会导致诸如哮喘,糖尿病和癌症以及自身免疫疾病,心血管疾病和呼吸系统等疾病。 出于这个原因,科学家们花了很多年试图理解控制免疫反应的机制。采用最新的DNA测序技术,来自Bat

JNCI:靶向整合素αvβ6治疗乳腺癌

近日,伦敦大学玛丽皇后学院(QMUL)研究人员揭示了整合素αvβ6在帮助乳腺癌细胞生长和扩散的基础性作用。这项研究发表在Journal of the National Cancer Institute杂志上,精确定位了这个分子可作为治疗最积极类型乳腺癌的一个可行的新靶标。 有五分之一的乳腺癌患者是HER2阳性,HER2阳性是一个特别积极类型的乳腺癌,其中HER2蛋白水平升高促使癌细胞生长和扩散

Baidu
map
Baidu
map
Baidu
map